艾美疫苗2024年实现收入约12.85亿元 同比增长8.2% 创新管线全面突破

智通财经
28 Mar

智通财经APP讯,艾美疫苗(06660)公布2024年业绩,收入约12.85亿元,同比增长8.2%。毛利约9.535亿元,同比增长5.8%。净亏损约2.78亿元,同比收窄85.7%。经营活动净现金流净流入近1亿元。其中,主营业务收入为12.85亿元,同比上升8.2%。上升主要是因为公司乙肝、甲肝及四价流脑疫苗产品的销售收入均实现增长。研发支出为3.63亿元,同比下降42.9%。主要是因为2024...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10